tirzepatide and fatty liver Dual GIP GLP-1 receptor agonist alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis

High-risk study participants High-risk participants were defined as those who had: a a known diseases or conditions known to increase the risk of colorectal cancer, such as colitis and Crohns disease Among all high-risk participants, GLP-1 drugs reduced the risk of colorectal cancer by 42% compared to aspirin

Welter R, Yu L, Yu CA

Switching to tirzepatide activates the GIP receptor in addition to GLP-1, engaging a parallel appetite and energy regulation circuit

Six studies (438 men) recorded sperm concentration and morphology, seven studies (459 men) reported total sperm motility and three studies (231 men) evaluated the progressive sperm motility after carnitine therapy